jm8b00240_si_001.pdf (1.4 MB)
18F‑Positron Emitting/Trimethine Cyanine-Fluorescent Contrast for Image-Guided Prostate Cancer Management
journal contribution
posted on 2018-04-20, 18:48 authored by Harikrishna Kommidi, Hua Guo, Fuad Nurili, Yogindra Vedvyas, Moonsoo M. Jin, Timothy D. McClure, Behfar Ehdaie, Haluk B. Sayman, Oguz Akin, Omer Aras, Richard Ting[18/19F]-4, an anionic GCPII/PSMA inhibitor
for image-guided intervention in prostate cancer, is described. [19F]-4 is radiolabeled with a radiochemical yield
that is ≥27% and a molar activity of 190 ± 50 mCi/μmol
in a <1 h, one-step, aqueous isotopic exchange reaction. [19F]-4 allows PSMA expression to be imaged by
fluorescence (FL) and [18F]-PET. PC3-PIP (PSMA-positive,
EC50 = 6.74 ± 1.33 nM) cancers are specifically delineated
in mice that bear 3 million (18 mg) PC3-PIP and PC3 (control, PSMA-negative)
cells. Colocalization of [18/19F]-4 PET, fluorescence,
scintillated biodistribution, and PSMA expression are observed.
